Objectives. Antiphospholipid antibodies (aPL) have been associated with syndromes involving thrombosis, fetal loss and thrombocytopenia. Genetic and environmental conditions are among the factors attributed to the cause of autoimmune diseases such as the antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The aim of this study was to determine whether these factors determine the prevalence of aPL.
The antiphospholipid syndrome (APS) is associated [9] . The presence of aPL in the normal population indicates that some trigger factor must be present to with possession of anticardiolipin antibodies (aCL) and/or lupus anticoagulant (LA) activity, with clinical induce disease. Variability in the prevalence of SLE in some ethnic features such as thrombocytopenia, thromboembolic phenomena and recurrent fetal loss [1, 2] . This may groups living in different parts of the world, and the presence of disease within families, suggest that both occur as a primary syndrome [primary APS (PAPS)] or secondary to an autoimmune condition, such as systemic environmental and genetic factors may trigger SLE induction in susceptible individuals or induce autoantilupus erythematosus (SLE ) [3, 4] . aCL are also detected in patients with SLE who do not have secondary APS body production [10] [11] [12] . The question may be raised as to whether production of autoantibodies alone is [5] .
Antibodies to phospholipids other than cardiolipin induced through prevailing conditions in the local environment or individual genetic constitution. The trend has have been detected in patients with APS and SLE, some associated with certain clinical features [6] [7] [8] .
been to focus on aCL in the characterization of PAPS and SLE/APS. Other anionic phospholipids to which Antiphospholipid antibodies (aPL) are also present in the normal population, unassociated with any disease antibodies may be directed are not routinely used in laboratory tests. We have determined the presence of antibodies to the ( Table 1) .
controls were deemed to be positive.
Relatives and spouses
Statistical analysis For the second part of the study, 43 healthy individuals Statistical analyses were performed using Biomedical were studied, 18 of whom were spouses and 25 were Statistics application software (Italian version). first-degree relatives of 14 patients with SLE/APS. Fifty Categorical analysis was performed by the chi-square healthy individuals (samples supplied by the National test. Blood Service, Colindale, UK ) were included as normal controls ( Table 1) .
Results

Methods
Patients aCL, aPI, aPG and aPS enzyme-linked immunosorbent assay (ELISA).
Half the wells of microtitre ELISA Table 2 shows the prevalence (percentage of subjects with aPL levels above the mean + 3 .. of 50 normal plates (Polysorp, Nunc, Life Technologies, Paisley, UK ) were coated with each of the following anionic phosphocontrols) of IgG/M/A aPI, aCL, aPS and aPG antibodies in the three patient groups; PAPS, SLE/APS, lipids at 50 mg/ml: cardiolipin (CL), phosphatidylinositol (PI ), phosphatidylglycerol (PG) and phosphatidylserine SLE, and normal controls. ence between patients with PAPS and SLE/APS (P < 0.0001 for aPI, P = 0.001 for aPS and P < 0.005 for aPG), and no significant difference between the two groups with respect to IgA aCL. There was no significant difference between patients with PAPS and SLE regarding the prevalence of IgA aCL, aPS and aPG. However, a difference occurred in IgA aPI (P < 0.0001). Fortytwo per cent of patients with SLE/APS and 19% of patients with SLE had IgA aPI. A significant difference between these two groups and patients with PAPS was evident, with respect to IgA aPI (P < 0.0001). There was no significant difference in the prevalence of IgA aPL between patients with PAPS and normal controls. When the prevalence of IgG was compared with IgM in the three patient groups, IgG aPI and aCL were more PAPS (P < 0.0001). IgG aCL was more prevalent than IgM aCL in patients with SLE. There was a significant difference between patients Relatives and spouses with PAPS and (i) SLE/APS (P < 0.0001), (ii) SLE (P < 0.0001) and (iii) normal controls (P < 0.0001) with Table 2 shows the prevalence (percentage of subjects with aPL levels above the mean + 3 .. of 50 normal regard to IgG aPL ( Fig. 1) . When considering IgM aPL, there was also a significant difference between controls) of IgG/M/A aPI, aCL, aPS and aPG antibodies in the first-degree relatives and spouses of patients PAPS and (i) SLE/APS (P < 0.0001, except aPI ); (ii) SLE (P < 0.0001) and (iii) normal controls with SLE/APS. Figure 4 illustrates the prevalence of IgG aPL in (P < 0.0001) (Fig. 2) . Figure 3 shows the prevalence of IgA aPL in the three patients with SLE/APS, their first-degree relatives and normal controls. There was no significant difference patient groups and normal controls. None of the patients with PAPS had IgA aPL. There was a significant differbetween the relatives and patients with SLE/APS regard-studied, antibodies against other negatively charged phospholipids have also been detected in human sera. This may be because these phospholipids share some similarities in structure, charge and configuration with CL [14] . We have shown a high prevalence of IgG aPL in patients with PAPS. This is significantly higher than in patients with SLE/APS and SLE ( Table 2, Fig. 1 ). Although some differences were seen, there was no significant difference between the prevalence of IgG and IgM aPL in the patient groups ( Table 2) . Interestingly, none of the patients with PAPS had IgA aPL.
We have also shown the presence of IgG aPL in the first-degree relatives of patients with SLE/APS. This was significantly different from the prevalence of IgG aPL in the healthy normal controls and generally not ( Fig. 4) . Although these individuals were considered 'normal', they have displayed some type of susceptibility to autoantibody production. It is of note that the genetic ing the prevalence of aPI, aCL and aPS. However, a contribution to autoantibody production may vary difference occurred in aPG (P < 0.03). There was a between patients with PAPS, SLE/APS and SLE, and significant difference between the relatives and normal only the relatives and spouses of patients with SLE/APS controls (P < 0.0001 for aPI and aCL; P = 0.001 for were studied. As reviewed elsewhere, relatives of patients aPS and aPG).
with autoimmune syndromes often have evidence of The prevalence of IgG aPL in patients with SLE/APS, autoantibody production without evidence of clinical their spouses and normal controls reveals a significant disease [15] . Mackworth-Young et al. found eight out difference between the spouses and patients with of 101 (7.9%) relatives had aCL [16 ] . More recently, SLE/APS (P < 0.0001, except aPI ) (Fig. 5) . There was Goldberg et al. reported IgG aCL in 23% of relatives no difference between the spouses and normal controls.
of aCL-positive patients [17] . When the prevalence of IgG was compared with IgM
The spouses of patients with SLE/APS showed a in the relatives and spouses, IgG aPI, aPS and aCL prevalence of IgG aPL not significantly different from were more prevalent than their IgM equivalents in the normal controls. The prevalence of IgG aPL in the relatives (P < 0.0001 for aPI and aPS; P < 0.03 for patients with SLE/APS was significantly different from aCL). IgG aPI was more prevalent than IgM aPI in the their spouses (Fig. 5) . These data indicate that although spouses (P < 0.003).
sharing environmental conditions with the patients with SLE/APS, the spouses were not predisposed to autoantiDiscussion body production. The prevalence of IgG aPL in the first-degree relatives We have determined the prevalence of IgG/M/A antiof patients with SLE/APS was higher than in the spouses bodies to the anionic phospholipids; CL, PI, PS and of patients with SLE/APS, suggesting that genetic pre-PG, in patients with PAPS, SLE/APS, SLE; and in the disposition to antibody production is likely to be more first-degree relatives and spouses of patients with important than a shared environmental influence. SLE/APS. Although aCL have been the most intensely It was notable that IgA aPI were present in 42% of patients with SLE/APS, 19% of patients with SLE but 0% of patients with PAPS. In patients with SLE/APS and SLE these figures were the highest incidence of any of the IgG/M/A aPL tested. This observation may be interesting if there is some, as yet undiscovered, link between the presence of IgA aPI and SLE. The question may be raised as to whether SLE alone, or with APS as a secondary syndrome, has some influence on IgA aPI which is non-existent when APS is a primary syndrome. Further work would involve the determination of the clinical significance of IgA aPI in patients with SLE/APS and SLE, compared with patients with PAPS. The results underline the heterogeneity of the aPL detectable in human sera. 
